

# Repetitive transcranial magnetic stimulation for adults with treatment resistant major depressive disorder

Technology Guidance from the MOH Medical Technology Advisory Committee

## Guidance Recommendations

The Ministry of Health's Medical Technology Advisory Committee has recommended repetitive transcranial magnetic stimulation (rTMS) therapy as treatment for adults (18 years or more) with treatment resistant major depressive disorder (TRD) in line with the following criteria:

- ✓ A single course of rTMS therapy of up to a maximum of 30 sessions as initial treatment for adults (aged 18 years or more) with a diagnosis of TRD:
  - Who failed to achieve satisfactory improvement despite adequate trialling of at least two different classes of antidepressants, unless these are contraindicated; AND
  - Who have undertaken psychological therapy when appropriate and feasible; AND
  - Who have not received treatment with rTMS previously.
  
- ✓ A single course of rTMS retreatment of up to a maximum of 30 sessions for adults with TRD:
  - Who have received initial treatment with rTMS and relapsed following remission or satisfactory clinical response, as assessed by a validated tool to measure the severity of major depressive disorder; AND
  - Retreatment should start no sooner than four months after the end of initial treatment.
  
- ✓ rTMS retreatment for patients with TRD who did not respond to rTMS initial treatment is not recommended.
  
- ✓ rTMS as maintenance treatment for patients with TRD is not recommended.

Published: 1 June 2026

## Funding status

Initial rTMS treatment and rTMS retreatment is recommended for subsidy for treatment of adults with TRD, in line with the abovementioned recommendations.

## Technology evaluation

- 1.1. At the March 2021 meeting, the MOH Medical Technology Advisory Committee (“the Committee”) considered the evidence presented for the technology evaluation of repetitive transcranial magnetic stimulation (rTMS) for treatment of adults with treatment resistant major depressive disorder (TRD). The Agency for Care Effectiveness (ACE) conducted the evaluation in consultation with clinical experts from public healthcare institutions. Published clinical and economic evidence for rTMS was considered in line with its registered indication.
- 1.2. The evidence was used to inform the Committee’s deliberations around five core decision-making criteria:
  - Clinical need of patients and nature of the condition;
  - Overall benefit of the technology for the patient and/or the system;
  - Cost-effectiveness (value for money), which considers the incremental benefit and cost of the technology compared to existing alternatives;
  - Estimated annual technology cost and the number of patients likely to benefit from the technology; and
  - Organisational feasibility, which covers the potential impact of adopting the technology, especially barriers for diffusion.
- 1.3. Additional factors, including social and value judgments, may also inform the Committee’s deliberations.

## Clinical need

- 2.1. The Committee noted that TRD is characterised by lack of satisfactory response to at least two adequate courses of antidepressants. Pharmacological treatment with antidepressants and psychological therapy remain the cornerstone of TRD management.
- 2.2. Currently, there is a lack of standardised antidepressant therapy recommended for TRD in Singapore. The available treatment strategies for TRD as third-line therapy include: optimisation of antidepressant dose; switching to similar or different class of antidepressant; combination of different classes of antidepressant; augmentation by adding non-antidepressants; and in some cases somatic therapies, such as an electroconvulsive therapy (ECT).
- 2.3. The Committee further noted that the likelihood of treatment success decreases after multiple trials with subsequent courses of antidepressants. In the target population for this evaluation, ECT is of limited use as it is mostly used in patients with psychotic major depressive disorder.

## Clinical effectiveness and safety

- 3.1. The Committee acknowledged that third-line antidepressant medication is the main comparator for rTMS in adults with TRD. The Committee noted that rTMS is a somatic, non-invasive neurostimulation and neuromodulation treatment technique. rTMS is often used in outpatient setting as adjunctive therapy with antidepressants and psychological therapy. However, in patients who are unable to tolerate or have contraindications to pharmacotherapy, rTMS can be administered as monotherapy. It can be used as initial treatment, retreatment, and maintenance treatment.
- 3.2. The Committee reviewed the available clinical evidence and agreed that, as a non-invasive treatment, rTMS has an acceptable safety profile with headaches being the most common adverse event. Supportive evidence showed that rTMS showed similar safety outcomes to pharmacological treatments.
- 3.3. The Committee noted that, compared to sham combined with antidepressants, rTMS combined with antidepressants demonstrated superiority in terms of clinical effectiveness. Based on a meta-analysis by Sehatzadeh et.al (2019) of randomised controlled trials (RCTs), rTMS combined with antidepressant was associated with a significant improvement in remission rates and depression scores compared with sham combined with antidepressants. The mean improvement in depression scores was considered clinically meaningful. No significant difference was observed for response rate, although the results numerically favoured rTMS combined with antidepressants.
- 3.4. The Committee noted that the evidence base for rTMS as retreatment is limited. Based on one single-arm open label study, rTMS retreatment resulted in improved outcomes in patients. Despite this limitation, there is a clinical need for rTMS retreatment in patients who have relapsed following remission or satisfactory clinical response to the initial course of rTMS. The Committee noted that only a single course of rTMS retreatment was recommended by ACE's reference agency – the Medical Services Advisory Committee (MSAC) in Australia.
- 3.5. The Committee agreed that the current evidence base for rTMS as ongoing maintenance treatment for TRD is currently premature.
- 3.6. The Committee noted that key limitations of the clinical evidence of rTMS include variable study parameters, treatment protocols, definition of remission, level of treatment resistance, and use of rTMS in monotherapy or as adjunctive therapy, and the small sample size included in the studies.

## Cost effectiveness

- 4.1. The Committee considered the cost-effectiveness of rTMS for treatment of adults with

TRD based on an in-house cost-effectiveness model comparing initial rTMS combined with antidepressants with antidepressants alone. The Committee noted that patients with TRD treated with rTMS experienced more quality adjusted life years (QALYs) but also incurred higher medical costs compared with patients with antidepressants alone.

- 4.2. In the base case analysis where only a single course of initial rTMS treatment was included, the incremental cost-effectiveness ratio (ICER) was less than \$15,000 per QALY gained. A scenario analysis included one course of rTMS as initial and retreatment each, rTMS became less costly and more effective (i.e. dominant) compared with antidepressants alone.
- 4.3. The Committee noted that the cost-effectiveness results were sensitive to probability of losing remission after antidepressant and rTMS therapy, and the health utility of remission after acute treatment.

## Estimated annual technology cost

- 5.1. The Committee noted that the annual cost impact to the public healthcare system was estimated to be less than SG\$0.5 million based on current rTMS services capacity.
- 5.2. The Committee noted that the budget impact for subsidising rTMS therapy is uncertain as the number of patients with TRD that is eligible for rTMS treatment may exceed the current utilisation due to capacity constraints of rTMS services in Singapore. The demand for rTMS services is likely to increase with the introduction of subsidy, given there is likely more eligible patients currently not seeking treatment. If more specialist outpatient clinics (SOCs) choose to offer rTMS treatment post subsidy, the estimated annual budget can exceed \$5M.

## Organisational feasibility

- 6.1. The Committee acknowledged the importance of the development and use of standard rTMS treatment protocols across all institutions. Institutions offering the rTMS service need to collect patient characteristics and rTMS treatment outcomes in electronic database. Treatment outcomes such as response, remission, cognitive outcomes, and adverse events should be measured in a systematic way, collated, and recorded in individual patient care records. The prescribing clinicians should clearly define the type of rTMS treatment (i.e. initial treatment, retreatment, or maintenance treatment) for subsidy eligibility assessment. The institutions should capture rTMS treatment type and number of rTMS sessions centrally. Patient outcomes should be measured at regular intervals that are not limited to baseline and at the end of rTMS treatment.

- 6.2. The Committee noted that institutions providing rTMS services should ensure proper and continued training and accreditation of rTMS practitioners. A rTMS operator who is trained to manage seizures should always be present with the patient and have immediate access to appropriate equipment to manage seizures before the arrival of emergency response teams.
- 6.3. As with all new clinical services, institutions that would like to offer rTMS services need to apply for MOH's approval for re-designation of the Levels of Medical Capabilities (LMC), if applicable. Institutions may submit their applications and their standard protocols to MOH Hospital Services Division (HSD). Applications will be assessed based on consideration to alignment with national interests, available manpower, infrastructure, supporting services, and clinical governance frameworks.

## Recommendations (March 2021)

- 8.1. Based on available evidence, the Committee recommended subsidising a single course of rTMS therapy of up to 24 sessions as initial treatment for adults (aged 18 years or more) with a diagnosis of TRD in line with the following criteria:
  - who have failed to achieve satisfactory improvement despite adequate trialling of at least two different classes of antidepressants, unless these are contraindicated; AND
  - who have undertaken psychological therapy when appropriate and feasible; AND
  - who have not received treatment with rTMS previously.
- 8.2. Given the unmet clinical need, the Committee recommended subsidy for a single course of rTMS retreatment of up to a maximum of 15 sessions for adults with TRD in line with the following criteria:
  - who have received initial treatment with rTMS and relapsed following remission or satisfactory clinical response, as assessed by a validated tool to measure severity of major depressive disorder; AND
  - Retreatment should start no sooner than four months after the end of initial treatment.

## Updated recommendations (April 2026)

- 9.1. At the December 2025 meeting, the Committee reviewed the latest available evidence for rTMS in the treatment of adults with TRD.
- 9.2. Based on the findings from ACE's 2025 evidence update, the Committee noted that initial rTMS treatment for adults with TRD was associated with statistically and clinically significant improvements, including reductions in depression scores and increased response and remission rates compared with sham treatment, irrespective of

concurrent antidepressant use. The evidence suggested that optimal therapeutic benefit was most likely achieved with 30 to 36 rTMS sessions. The Committee noted that most published studies did not distinguish between initial rTMS treatment and rTMS retreatment.

- 9.3. The Committee reviewed the evidence update on maintenance rTMS and agreed that, given the uncertainty about the optimal patient population, treatment approaches and protocols for maintenance rTMS, there was insufficient evidence to draw a definitive conclusion about the clinical effectiveness of maintenance rTMS.
- 9.4. The Committee considered the cost-effectiveness of rTMS for the treatment of adults with TRD, based on an updated in-house cost-effectiveness model. The model compared a treatment strategy of 30 initial rTMS sessions with 15 rTMS retreatment sessions against third-line antidepressants, as well as the current subsidised strategy of 24 initial rTMS sessions with 15 rTMS retreatment sessions. The Committee considered that rTMS remained cost-effective in these settings.
- 9.5. The Committee noted that the annual cost impact of increasing the number of subsidised initial rTMS treatment sessions from 24 to 30 and subsidised rTMS retreatment sessions from 15 to 30 to the public healthcare system was estimated to be between SG\$1 million to less than SG\$3 million, based on the projection of approximately 45 eligible patients in Singapore who would benefit from Government subsidy.
- 9.6. Overall, the Committee considered the clinical and economic evidence presented in ACE's evidence update and recommended extending the subsidy for initial rTMS treatment from 24 to 30 sessions, and for rTMS retreatment from 15 to 30 sessions. The Committee agreed that maintenance treatment should not be subsidised.

## VERSION HISTORY

### Guidance on repetitive transcranial magnetic stimulation for adults with treatment resistant major depressive disorder

This Version History is provided to track any updates or changes to the guidance following the first publication date. It is not part of the guidance.

- 1. Publication of guidance**  
Date of Publication 2 Jan 2021
- 2. Guidance updated due to the extension of subsidy from initial rTMS from 24 to 30 sessions and rTMS retreatment from 15 to 30 sessions.**  
Date of Publication 1 Jun 2026

 Agency for Care Effectiveness - ACE  Agency for Care Effectiveness (ACE)

#### About the Agency

The Agency for Care Effectiveness (ACE) was established by the Ministry of Health (Singapore) to drive better decision-making in healthcare through health technology assessment (HTA), clinical guidance, and education.

As the national HTA agency, ACE conducts evaluations to inform government funding decisions for treatments, diagnostic tests and vaccines, and produces guidance for public hospitals and institutions in Singapore.

The guidance is not, and should not be regarded as, a substitute for professional or medical advice. Please seek the advice of a qualified healthcare professional about any medical condition. The responsibility for making decisions appropriate to the circumstances of the individual patient remains with the healthcare professional.

*Find out more about ACE at [www.ace-hta.gov.sg/about](http://www.ace-hta.gov.sg/about)*

#### © Agency for Care Effectiveness, Ministry of Health, Republic of Singapore

All rights reserved. Reproduction of this publication in whole or in part in any material form is prohibited without the prior written permission of the copyright holder. Requests to reproduce any part of this publication should be addressed to:

Agency for Care Effectiveness, Ministry of Health  
Email: [ACE\\_HTA@moh.gov.sg](mailto:ACE_HTA@moh.gov.sg)

In citation, please credit the "Agency for Care Effectiveness, Ministry of Health, Singapore" when you extract and use the information or data from the publication.